BRIEF published on 06/15/2026 at 19:35, 3 months 18 days ago Oxurion: Exagis adopted by Pierre Fabre Biopharmaceutical Clinical Data Oxurion Exaggerate Pierre Fabre
BRIEF published on 06/15/2026 at 19:35, 3 months 18 days ago Oxurion's Exagis Platform Gains Major Market Validation with Pierre Fabre Laboratories Data Management Pharmaceutical Oxurion Pierre Fabre Exagis Platform
PRESS RELEASE published on 06/15/2026 at 19:30, 3 months 18 days ago Major market validation: Pierre Fabre Laboratories uses Oxurion's Exagis Platform Oxurion NV announces Pierre Fabre Laboratories utilizing Exagis clinical data management platform by Axiodis CRO, enhancing efficiency and compliance. Exagis adapts to various study configurations Oxurion NV Clinical Data Management Axiodis CRO Exagis Pierre Fabre Laboratories
BRIEF published on 06/10/2026 at 18:05, 3 months 23 days ago Oxurion receives a transparency notification from Atlas Special Opportunities II LLC Shares Transparency Euronext Brussels Oxurion Atlas Special Opportunities II LLC
BRIEF published on 06/10/2026 at 18:05, 3 months 23 days ago Oxurion Receives Notification on Shareholding Change Shares Transparency Notification Belgium Atlas Special Opportunities Oxurion
PRESS RELEASE published on 06/10/2026 at 18:00, 3 months 23 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV received a transparency notification from Atlas Special Opportunities II, LLC regarding shareholding crossing the threshold. Oxurion is a technology-enabled clinical research company Clinical Research Transparency Notification Shareholding Oxurion NV Atlas Special Opportunities II, LLC
BRIEF published on 06/08/2026 at 21:05, 3 months 25 days ago Oxurion Unveils Software-Driven Growth Strategy with Exagis Oxurion Clinical Data Management Exagis Software Strategy EClinical Platform
BRIEF published on 06/08/2026 at 21:05, 3 months 25 days ago Oxurion announces its software strategy with Exagis Growth Strategy Clinical Research Software Oxurion Exaggerate
PRESS RELEASE published on 06/08/2026 at 21:00, 3 months 25 days ago Oxurion launches a software-driven growth strategy with Exagis Oxurion NV announces the software-driven growth strategy launch centered on Exagis, its proprietary clinical research platform. The platform evolves into a broad CDMS commercially serving clinical development market Oxurion NV Exagis Clinical Research Platform Software-driven Growth Strategy CDMS
BRIEF published on 06/03/2026 at 18:05, 4 months ago Oxurion Announces the Results of its Annual General Meeting Pharmaceutical Investments General Assembly Results Oxurion
Published on 10/03/2026 at 02:35, 19 hours 52 minutes ago Jaguar Health Announces a Special Stock Dividend
Published on 10/02/2026 at 13:50, 1 day 8 hours ago AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 1 day 9 hours ago Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 1 day 9 hours ago Alaska Energy Metals Appoints Independent Director, Thomas Benson
Published on 10/03/2026 at 15:45, 6 hours 41 minutes ago Huawei Highlights Continuous Innovation, Securing Competitive Edge Through Technological Breakthroughs
Published on 10/02/2026 at 23:55, 22 hours 31 minutes ago IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY
Published on 10/02/2026 at 20:23, 1 day 2 hours ago EQS-Adhoc: Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding
Published on 10/02/2026 at 19:46, 1 day 2 hours ago innoscripta SE: Update on the Tax Authorities’ Investigation – Business Operations Continue as Usual – Full Transparency Assured – Invitation to Shareholders for an In-Person Product Presentation
Published on 10/02/2026 at 18:00, 1 day 4 hours ago EQS-Adhoc: AMUNDI PHYSICAL GOLD ETC (the “ETC”): Release of the first Supplemental Base Prospectus (the “Supplemental”)
Published on 10/02/2026 at 17:45, 1 day 4 hours ago Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/01/2026 at 19:00, 2 days 3 hours ago AMA CORP PLC reduces its cost base while preserving XpertEye’s key functions
Published on 10/01/2026 at 18:40, 2 days 3 hours ago Monthly disclosure of the total number of shares and voting rights - September 2026
Published on 10/01/2026 at 18:05, 2 days 4 hours ago Covivio - Information on total number of voting rights and share capital
